| Previous Close | 81.84 |
| Open | 81.76 |
| Bid | 82.49 x 300 |
| Ask | 82.50 x 100 |
| Day's Range | 81.46 - 82.58 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 2,242,295 |
| Avg. Volume | 3,653,068 |
| Market Cap | 86.85B |
| Beta | 0.17 |
| PE Ratio (TTM) | 39.93 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.53%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Forbes•4 hours ago
Diabetes Crisis Continues To Rage, But Biopharma's Response Is Tepid
However, if you were running an R&D organization, would you use your precious resources to invest in diabetes R&D, or would you look at other important areas like cancer and rare diseases, where the need is great but the ultimate development costs are less?
- Thomson Reuters StreetEvents•19 hours ago
Edited Transcript of LLY earnings conference call or presentation 25-Jul-17 1:00pm GMT
Q2 2017 Eli Lilly and Co Earnings Call
- Barrons.com•yesterday
Eli Lilly: The Competition is Just Too Darn Intense!
Yesterday, shares fop Eli Lilly (LLY) dropped 3% after the pharmaceutical giant beat earnings forecasts but said that a new drug application for a rheumatoid arthritis treatment had been delayed. Leerink ...
